You just read:

BioMarin Plans Regulatory Submissions for Marketing Authorization of Valoctocogene Roxaparvovec to Treat Severe Hemophilia A in 4Q 2019 in both U.S. and Europe

News provided by

BioMarin Pharmaceutical Inc.

Jul 08, 2019, 08:01 ET